Alivus Life Sciences has announced that its Board of Directors will convene on May 14, 2026. The meeting agenda includes the review and approval of the company’s audited financial results for the quarter and fiscal year ending March 31, 2026. Additionally, the board will discuss the potential recommendation of a dividend on equity shares for the concluded financial year.
Upcoming Board Meeting Details
Alivus Life Sciences (formerly Glenmark Life Sciences) has confirmed that a board meeting is scheduled for Thursday, May 14, 2026. This meeting is primarily focused on the finalization of the company’s financial performance for the period covering both the final quarter and the entire fiscal year ending March 31, 2026.
Financial Results and Dividend Considerations
Key agenda items for the board include the evaluation of the audited financial results for the year. Beyond reporting, the board is expected to evaluate and potentially recommend a dividend payment to shareholders for the financial year ended March 31, 2026, reflecting the company’s capital allocation strategy following its annual performance review.
Trading Window Closure
In adherence to internal corporate governance policies, the company has mandated a closure of its trading window. The window will remain closed for designated persons starting April 01, 2026, and will remain in effect until May 16, 2026, inclusive. This measure is implemented to ensure the confidentiality of financial information leading up to the public disclosure of the results.
Source: BSE
